Medical specialists have renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS).

The change aims to shift the clinical focus toward the endocrine and metabolic features of the condition. By moving away from a name centered on ovarian cysts, advocates hope to reduce patient stigma and improve the accuracy of diagnosis and treatment for the millions of women affected worldwide [1].

The announcement took place earlier this month at the European Congress of Endocrinology. This rebranding follows more than 10 years of research and advocacy [2] to better characterize the syndrome's diverse features.

For years, the term "polycystic" created a misconception that the condition was primarily defined by an increase in abnormal cysts on the ovary. Some reports indicate there is actually no increase in abnormal cysts, and the metabolic components of the syndrome were often unappreciated by clinicians and patients alike [3].

The new terminology, PMOS, explicitly highlights the polyendocrine and metabolic nature of the disorder. Experts said this provides a clearer picture of how the syndrome affects the body beyond the reproductive system.

By centering the metabolic aspects, the medical community seeks to ensure that patients receive comprehensive care that addresses hormonal imbalances, and insulin resistance. This shift is intended to break a long-standing stigma associated with the presence of cysts [4].

“The condition formerly known as PCOS has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS)”

The transition from PCOS to PMOS represents a fundamental shift in how the medical community views the disorder, moving it from a localized ovarian issue to a systemic endocrine and metabolic condition. This change may lead to more standardized diagnostic criteria and a broader approach to treatment that prioritizes metabolic health over the mere presence of ovarian cysts.